Risk factors

Edgewise Therapeutics (EWTX) risk factors

Item 1A of every Edgewise Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open EWTX in Gloom →
Edgewise Therapeutics' chart, financials and news, free in your browser.Open EWTX in Gloom →
  • FY2025 10-K risk factors
    86 risks8 new6 dropped23 reworded

    Edgewise Therapeutics highlights clinical trial execution risks for lead candidates sevasemten and EDG-7500. New disclosures address foreign regulatory hurdles, international trial locations, and updated U.S. tax legislation.

    Filed Feb 26, 2026
  • FY2024 10-K risk factors
    84 risks

    Edgewise Therapeutics is an early-stage biopharmaceutical company with no approved commercial products and significant accumulated losses.

    Filed Mar 03, 2025